FTC, Boehringer Wrangle Over Generics Settlement Docs

Law360, Washington (December 9, 2011, 7:30 PM EST) -- The Federal Trade Commission, on the hunt for documents relating to a patent settlement it is investigating between Boehringer Ingelheim Pharmaceuticals Inc. and Barr Pharmaceuticals Inc. that may have unlawfully delayed generic drugs, told a judge Friday that the documents contained factual material, not just attorneys' mental impressions.

In October 2009 the FTC accused Boehringer in Washington federal court of using a number of tactics to delay its investigation, such as inappropriately redacting documents and failing to conduct a careful and thorough search.

The agency's subpoena,...
To view the full article, register now.